Novogenia AG (ticker symbol: 7V0, formerly Darwin AG), an international healthcare company specializing in human genetics and personalized products, has announced the U.S. market launch of its new MGT Plus methylation test. This launch, in collaboration with U.S. partner 10X Health, extends their joint product pipeline and reinforces their international cooperation in innovative genetic analysis and longevity.
Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions in the human body. As an integral part of key metabolic pathways, it can significantly influence the function and processing of a wide range of biological molecules, including vitamins and neurotransmitters. While commercially available tests typically analyze only a limited number of relevant genes, MGT Plus covers a total of 27 genes, providing a more comprehensive picture of methylation processes across six interconnected biological pathways: energy and nutrient metabolism, stress and neurotransmitter regulation, as well as vascular, immune, and cellular health. This expanded scope allows for more precise insights into key biochemical processes.
“With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies. Our close collaboration with our U.S. partner 10X Health underscores our commitment to making scientific innovations accessible internationally and actively advancing personalized approaches to preventive health,” says Dr. Daniel Wallerstorfer, CEO of Novogenia AG.
The global direct-to-consumer testing market is experiencing strong growth: in 2025, the market size had already reached approximately $4.7 billion and is projected to grow to more than $16.0 billion by 2033. The genetic testing sector is developing particularly dynamically; with a share of over 40 percent, it already represents the largest segment of the market today. North America plays a leading role in this sector and accounted for around 50 percent of the global market volume in 2025. This development is driven by the growing interest in personalized health information, prevention, and individually tailored health services.
The introduction of MGT Plus in the U.S. market is a strategic move that aligns with these market trends. By offering a more comprehensive methylation analysis, Novogenia aims to cater to the increasing demand for detailed genetic insights that can inform personalized health strategies. The collaboration with 10X Health is expected to facilitate the distribution and accessibility of this advanced test in North America, where the market for genetic testing is particularly robust.
Novogenia's expansion of its international product portfolio with MGT Plus underscores its commitment to leveraging genetic research to improve preventive health measures. The company's focus on methylation, a process that affects various biological functions, positions it at the forefront of personalized medicine. As the market for direct-to-consumer genetic testing continues to grow, Novogenia's comprehensive approach may set a new standard in the industry, offering consumers a more detailed understanding of their genetic predispositions and potential health risks.
